Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 5;11(7):890.
doi: 10.3390/brainsci11070890.

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study

Antonio Ziello  1 , Cristina Scavone  2   3 , Maria Elena Di Battista  1   4 , Simona Salvatore  1   4 , Daniele Di Giulio Cesare  1 , Ornella Moreggia  1 , Lia Allegorico  1 , Anna Sagnelli  4 , Stefano Barbato  4 , Valentino Manzo  4 , Annalisa Capuano  2   3 , Giorgia Teresa Maniscalco  1   4
Affiliations

Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study

Antonio Ziello et al. Brain Sci. .

Abstract

Background: The so-called "vaccine hesitancy" still represents a common phenomenon that undermines the effectiveness of vaccination campaigns. In 2020, the Italian Medicines Agency recommended to bring forward the flu vaccination campaign, whose importance was also emphasized for patients with Multiple Sclerosis (MS). We aimed to assess vaccination behavior in patients with MS to prepare for the upcoming SARS-CoV-2 vaccination challenge.

Methods: This is an observational study carried out in one MS clinical Centre that enrolled all MS patients who were eligible for any of the flu vaccines recommended by the Italian medicines Agency.

Results: 194 patients were enrolled. Patients' mean age was 43.9 years and 66% were female. Comorbidities, mainly represented by non-autoimmune diseases, were identified in 52% of patients. Almost all patients were receiving a DMT during the study period, mainly dimethyl fumarate, natalizumab, teriflunomide, and interferon. Out of 194 patients, 58.2% accepted to be vaccinated. No statistically significant differences were found, except for the use of natalizumab, which was higher among vaccinated patients.

Conclusion: The results of our study emphasize the importance of education and communication campaigns addressed both to healthcare providers and patients with MS, especially considering that MS patients are currently receiving COVID-19 vaccinations.

Keywords: hesitancy; influenza vaccine; multiple sclerosis; observational study.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. G.T.M. received personal compensation from Serono, Biogen, Novartis, Roche, and TEVA for public speaking and advisory boards. A.Z., C.S., M.E.D.B., S.S., D.D.G.C., O.M., L.A., A.S., S.B., V.M. and A.C. have no disclosures.

References

    1. Zheng C., Kar I., Chen C.K., Sau C., Woodson S., Serra A., Abboud H. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020;34:1–18. doi: 10.1007/s40263-020-00756-y. - DOI - PMC - PubMed
    1. McNicholas N., Chataway J. Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J. Neurol. 2011;258:1545–1547. doi: 10.1007/s00415-011-5944-x. - DOI - PubMed
    1. Geier D.A., Geier M.R. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38:295–301. doi: 10.1080/08916930500144484. - DOI - PubMed
    1. Mailand M.T., Frederiksen J.L. Vaccines and Multiple Sclerosis: A Systematic Review. J. Neurol. 2017;264:1035–1050. doi: 10.1007/s00415-016-8263-4. - DOI - PubMed
    1. Pool V., Gordon D.M., Decker M. Methodological issues with the risk of relapse study in patients with multiple sclerosis after yellow fever vaccination. Arch. Neurol. 2012;69:144. doi: 10.1001/archneurol.2011.1519. - DOI - PubMed

LinkOut - more resources